Immune‐Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat

Martin, Paul

doi:10.1002/hep.30654

Cited by 5 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is also known as HBeAg-positive chronic HBV infection. 103 , 104 Patients are in the immune tolerance phase and are generally younger. They are positive for HBeAg, with high levels of HBV DNA (usually >2×10 7 IU/mL) and serum HBsAg (usually >1×10 4 IU/mL).…”

Section: Clinical Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for Prevention and Treatment of Chronic Hepatitis B

Wang

Duan

2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update the guidelines for the prevention and treatment of chronic hepatitis B (CHB). The current guidelines cover recent advances in basic, clinical, and preventive studies of CHB infection and consider the actual situation in China. These guidelines are intended to provide support for the prevention, diagnosis, and treatment of CHB.

show abstract

Section: Clinical Diagnosismentioning

confidence: 99%

“…This is also known as HBeAg-positive chronic HBV infection 103,104. Patients are in the immune tolerance phase and are generally younger.…”

mentioning

confidence: 99%

Guidelines for Prevention and Treatment of Chronic Hepatitis B

Wang

Duan

2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

show abstract

“…The World Health Organization (WHO) developed ambitious targets for the elimination of HBV as a public health threat by 2030 [ 32 ]. However, the choice of treatment timing for CHB patients remains a point of contention [ 13 ]. To solve this problem, it is crucial to find more biomarkers to distinguish the natural history of chronic HBV infection [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…These studies suggest that therapeutic interventions should be considered in some IT-phase patients to minimize further hepatocyte damage, however current diagnostic indicators are unable to accurately screen these patients. Although serial monitoring of ALT, HBeAg, and HBV DNA levels are required in clinical patients, some individuals with chronic HBV infection fall into an indeterminate grey area that makes it difficult to determine whether to use antiviral therapy [ [12] , [13] , [14] ]. Biomarkers for the diagnosis and treatment of HBV infection do not meet current clinical needs [ 3 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach

Xun

Yao

Zhu

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…These patients were followed up 3 times in 1 year with an interval of more than 3 months. Patients with AsC were diagnosed and excluded as previous reported [ 23 , 24 ]. The clinical characteristics of these 10 patients are summarized in Table 1 and Supplementary Table 2 .…”

Section: Methodsmentioning

confidence: 99%

Integrated Analysis of Long Noncoding RNA Expression Profiles in Acute-on-Chronic Liver Failure

Cheng

Ouyang

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

People infected with chronic hepatitis B virus (HBV) might progress to acute-on-chronic liver failure (ACLF) with a high fatality rate. Long noncoding RNAs (lncRNAs) are involved in human diseases, but it is unknown whether lncRNAs are involved in the progression of chronic HBV infection to ACLF. Hence, this study is aimed at systemically identifying and characterizing the landscape and the molecular mechanism of lncRNAs in the pathogenesis of chronic HBV infection progress to ACLF. RNA sequencing (RNA-Seq) of peripheral blood samples from 5 ACLF and 5 HBV infection patients was performed. We detected 9733 lncRNAs, including 406 annotated lncRNAs and 9327 novel lncRNAs. A total of 407 lncRNAs were found to be significantly dysregulated in the patients with ACLF as compared with those in the chronic HBV infection patients. The flanking protein-coding genes of differentially expressed lncRNAs were enriched with pathways that might contribute to the pathogenesis of ACLF, such as the WNT signaling pathway. Furthermore, 9 selected differentially expressed lncRNAs validated by the qRT-PCR, showing that the expression patterns of these 9 lncRNAs were consistent with the RNA-Seq data. Four selected differentially expressed lncRNAs were also validated in another patient cohort comprising 80 patients with ACLF and 65 patients with chronic HBV infection. Aberrant lncRNAs might be used to develop novel diagnostic biomarkers or drug targets for ACLF.

show abstract

Immune‐Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat

Cited by 5 publications

References 10 publications

Guidelines for Prevention and Treatment of Chronic Hepatitis B

Guidelines for Prevention and Treatment of Chronic Hepatitis B

Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach

Integrated Analysis of Long Noncoding RNA Expression Profiles in Acute-on-Chronic Liver Failure

Contact Info

Product

Resources

About